Jasper Therapeutics stock falls as BTIG lowers price target to $7 from $20
NegativeFinancial Markets

Jasper Therapeutics has seen a significant drop in its stock price after BTIG lowered its price target from $20 to $7. This adjustment reflects concerns about the company's future performance and market position, which could impact investor confidence and the company's ability to raise funds for ongoing projects. Such changes in stock targets are crucial as they can influence trading decisions and overall market sentiment.
— Curated by the World Pulse Now AI Editorial System